Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Uveal melanoma (UM) is frequently driven by mutations in GNAQ, GNA11, PLCB4, or CYSLTR2.
• While BRAFV600E-targeted therapy is effective in cutaneous melanoma, direct oncoprotein inhibition is nascent in UM.
• UM driver mutations converge on actionable pathways like PKC/MAPK, PI3K/AKT, and YAP/TAZ.

Purpose of the Study:

• To summarize recent studies on UM-targeted therapies.
• To analyze the reasons behind the disappointing results of clinical trials.
• To identify potential new therapeutic targets for UM aggressiveness.

Main Methods:

• Review of recent preclinical and clinical studies on UM targeted therapies.
• Analysis of common downstream signaling pathways affected by UM driver mutations.
• Investigation of BAP1 loss and its role in UM metastatic progression and chromatin structure.

Main Results:

• Preclinical successes in targeting MAPK and PKC pathways were not replicated in early clinical studies.
• Clinical trials of targeted and immune therapies for UM have yielded disappointing outcomes.
• BAP1 loss impacts chromatin structure, suggesting potential for histone deacetylase inhibitors.

Conclusions:

• Current targeted therapies for UM have faced significant challenges and failures in clinical settings.
• Understanding the convergence of UM mutations on signaling pathways is crucial for developing effective treatments.
• Hyperexpressed molecules involved in UM aggressiveness represent promising avenues for novel therapeutic strategies.